Implications for multiple sclerosis in the era of the Affordable Care Act: a clinical overview.
- Megan E. Maroney, S. Hunter
- Medicine, PsychologyAmerican Journal of Managed Care
- 28 December 2014
Current and future treatments may help limit the personal and societal costs of MS by delaying disability and disease progression.
An update on current treatment strategies and emerging agents for the management of schizophrenia.
- Megan E. Maroney
- Psychology, MedicineAmerican Journal of Managed Care
- 1 March 2020
The schizophrenia treatment guidelines, current treatment strategies, and emerging agents for the management of schizophrenia are summarized.
Pharmacologic Treatment Options for Insomnia in Patients with Schizophrenia
- Lauren Stummer, Marija Markovic, Megan E. Maroney
- Medicine, PsychologyMedicines
- 11 August 2018
Overall, this review confirmed that there are a few evidence-based options to treat insomnia in patients with schizophrenia, including selecting a more sedating second-generation antipsychotic such as paliperidone, or adding melatonin or eszopiclone.
Brexpiprazole: A New Treatment Option for Schizophrenia and Major Depressive Disorder
- Marija Markovic, Alyssa Gallipani, Krina H. Patel, Krina H. Patel, Megan E. Maroney, Megan E. Maroney
- Psychology, Medicine
- 1 April 2017
The pharmacology and clinical data for brexpiprazole in schizophrenia and major depressive disorder (MDD) and an English-language literature search using PubMed and Google Scholar are reviewed.
Teriflunomide for the Treatment of Relapsing Multiple Sclerosis
- L. Brunetti, M. Wagner, Megan E. Maroney, M. Ryan
- MedicineThe Annals of Pharmacotherapy
- 1 September 2013
Teriflunomide is an effective and safe oral treatment option for relapsing MS and can be used as monotherapy or added to an interferon or glatiramer acetate.
Brexpiprazole
- Marija Markovic, Alyssa Gallipani, Krina H. Patel, Megan E. Maroney
- MedicineReactions weekly
- 1 April 2017
Objective: To review the pharmacology and clinical data for brexpiprazole in schizophrenia and major depressive disorder (MDD). Data Sources: An English-language literature search using PubMed and…
A Retrospective Multicenter Evaluation of Clozapine Use in Pediatric Patients Admitted for Acute Psychiatric Hospitalization.
- Laura M Steinauer, J. Leung, J. V. Vande Voort
- Medicine, PsychologyJournal of child and adolescent…
- 1 November 2018
In this cohort, 95% of pediatric patients admitted with or started on clozapine during an acute psychiatric hospitalization were discharged on the medication and the high incidence of adverse events should reinforce the need for vigilant monitoring.
Brexpiprazole in the treatment of schizophrenia and agitation in Alzheimer's disease.
- Lauren Stummer, Marija Markovic, Megan E. Maroney
- Psychology, MedicineNeurodegenerative Disease Management
- 3 July 2020
Well-tolerated brexpiprazole expands the armamentarium of treatment options available for schizophrenia and adjunctive treatment of major depressive disorder, and has recently been studied for the treatment of agitation in Alzheimer's dementia.
Topiramate in the treatment of Prader-Willi syndrome: A case report.
- N. East, Megan E. Maroney
- Medicine, PsychologyMental Health Clinician
- 3 January 2017
This case demonstrates the positive effects of topiramate for reducing aggression and demand for food in a child with PWS most likely due to an increase in satiety.
Evaluation of the use of electrocardiogram monitoring in patients on psychotropic medications that have a risk of QT prolongation
- S. Girgis, Megan E. Maroney, Mei T. Liu
- Medicine, PsychologyMental Health Clinician
- 29 June 2016
Many inpatients on psychiatric medications received multiple medications with a risk of TdP, but not all received monitoring through baseline or repeat EKGs when warranted, which can help improve the monitoring and management of QT prolongation.
...
...